%0 Journal Article
%T Cognitive Profiles in Treatment-Resistant Late-Life Depression and their Impact on Treatment Outcomes.
%A Göke K
%A McClintock SM
%A Mah L
%A Rajji TK
%A Lee HH
%A Nestor SM
%A Downar J
%A Noda Y
%A Daskalakis ZJ
%A Mulsant BH
%A Blumberger DM
%J Biol Psychiatry Cogn Neurosci Neuroimaging
%V 0
%N 0
%D 2024 Jul 23
%M 39053577
%F 6.05
%R 10.1016/j.bpsc.2024.07.009
%X <B>BACKGROUND: </B>Late-life depression (LLD) is associated with cognitive impairment, yet substantial heterogeneity exists among patients. Data on the extent of cognitive impairments is inconclusive, particularly in patients with treatment-resistant depression (TRD). We investigated the cognitive profiles of patients with treatment-resistant vs. nonresistant LLD and aimed to identify distinct cognitive subgroups. Additionally, we examined whether cognitive subgroups differentially responded to treatment with bilateral repetitive transcranial magnetic stimulation (rTMS).<BR><B>METHODS: </B>165 patients with LLD were divided into treatment-resistant and nonresistant groups and compared to healthy controls (HC) on measures of executive function, information processing speed, verbal learning, and memory. Cluster analysis identified subgroups based on cognitive scores. Demographic and clinical variables, as well as outcomes with bilateral rTMS, were compared between cognitive subgroups.<BR><B>RESULTS: </B>Patients with LLD, particularly TRD, exhibited significantly worse cognitive performance than HC. A three-cluster solution was found, including "Cognitively Intact" (n = 89), "Cognitively Diminished" (n = 29), and "Impaired Memory" (n = 47) subgroups. Both the "Cognitively Diminished" and "Impaired Memory" subgroups had more anxiety symptoms and a higher proportion of patients with TRD than the "Cognitively Intact" group, though the latter did not survive multiple comparison correction. No significant differences were observed in outcomes to rTMS treatment.<BR><B>CONCLUSIONS: </B>Patients with LLD exhibited impairments across cognitive domains, which were more pronounced in TRD. Three identified cognitive subgroups responded similarly to rTMS treatment, indicating its effectiveness across cognitive profiles, especially when medications are not tolerated. Future research should examine the relationship among cognitive subgroups, cognitive decline, and neurodegeneration.